Last updated: 29 April 2020 at 7:21pm EST

Dr. Bruce D. Given Net Worth




The estimated Net Worth of Bruce D Given is at least $30.8 Million dollars as of 27 April 2020. Dr Given owns over 5,401 units of Arrowhead Pharmaceuticals stock worth over $17,814,286 and over the last 13 years he sold ARWR stock worth over $12,498,927. In addition, he makes $486,308 as Advisor at Arrowhead Pharmaceuticals.

Dr Given ARWR stock SEC Form 4 insiders trading

Dr has made over 14 trades of the Arrowhead Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 5,401 units of ARWR stock worth $216,040 on 27 April 2020.

The largest trade he's ever made was selling 242,834 units of Arrowhead Pharmaceuticals stock on 8 February 2019 worth over $3,895,057. On average, Dr trades about 30,165 units every 33 days since 2012. As of 27 April 2020 he still owns at least 850,730 units of Arrowhead Pharmaceuticals stock.

You can see the complete history of Dr Given stock trades at the bottom of the page.





Dr. Bruce D. Given biography

Dr. Bruce D. Given is the Advisor at Arrowhead Pharmaceuticals.

What is the salary of Dr Given?

As the Advisor of Arrowhead Pharmaceuticals, the total compensation of Dr Given at Arrowhead Pharmaceuticals is $486,308. There are 10 executives at Arrowhead Pharmaceuticals getting paid more, with Christopher Anzalone having the highest compensation of $2,216,260.



How old is Dr Given?

Dr Given is 66, he's been the Advisor of Arrowhead Pharmaceuticals since . There are 2 older and 15 younger executives at Arrowhead Pharmaceuticals. The oldest executive at Arrowhead Pharmaceuticals Inc. is Dr. Mark Seefeld, 67, who is the Head of Toxicology & VP.

What's Dr Given's mailing address?

Bruce's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.

Insiders trading at Arrowhead Pharmaceuticals

Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.



What does Arrowhead Pharmaceuticals do?

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing



What does Arrowhead Pharmaceuticals's logo look like?

Arrowhead Pharmaceuticals Inc. logo

Complete history of Dr Given stock trades at Arrowhead Pharmaceuticals

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
27 Apr 2020 Bruce D Given
Chief Operating Officer
Sale 5,401 $40.00 $216,040
27 Apr 2020
850,730
20 Apr 2020 Bruce D Given
Chief Operating Officer
Sale 23,515 $40.00 $940,600
20 Apr 2020
851,734
6 Jan 2020 Bruce D Given
Chief Operating Officer
Sale 35,613 $60.13 $2,141,410
6 Jan 2020
858,993
1 Mar 2019 Bruce D Given
Chief Operating Officer
Option 42,500 $2.01 $85,425
1 Mar 2019
687,106
25 Feb 2019 Bruce D Given
Chief Operating Officer
Option 42,500 $2.01 $85,425
25 Feb 2019
687,106
15 Feb 2019 Bruce D Given
Chief Operating Officer
Sale 68,750 $17.86 $1,227,875
15 Feb 2019
644,606
8 Feb 2019 Bruce D Given
Chief Operating Officer
Sale 242,834 $16.04 $3,895,057
8 Feb 2019
670,856
5 Feb 2019 Bruce D Given
Chief Operating Officer
Sale 22,500 $14.48 $325,800
5 Feb 2019
847,856
1 Feb 2019 Bruce D Given
Chief Operating Officer
Sale 28,500 $13.85 $394,725
1 Feb 2019
870,356
22 Jan 2019 Bruce D Given
Chief Operating Officer
Sale 169,500 $13.54 $2,295,030
22 Jan 2019
898,856
14 Jan 2019 Bruce D Given
Chief Operating Officer
Sale 42,666 $14.40 $614,390
14 Jan 2019
1,068,356
1 Jan 2019 Bruce D Given
Chief Operating Officer
Sale 20,000 $11.98 $239,600
1 Jan 2019
1,098,356
5 Mar 2018 Bruce D Given
Chief Operating Officer
Sale 20,000 $6.73 $134,600
5 Mar 2018
908,356
1 Jan 2018 Bruce D Given
Chief Operating Officer
Sale 20,000 $3.69 $73,800
1 Jan 2018
928,356


Arrowhead Pharmaceuticals executives and stock owners

Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: